Skip to Content
Biotechnology

What researchers learned from deliberately giving people covid

The first human “challenge trial” for covid has given some helpful insights into how infection progresses.

February 3, 2022
mobile testing covid NYC
A health care worker tests a woman for COVID-19 in New York CityAP

The news: People who’ve caught covid become infectious far more quickly than previously believed, according to the world’s first “human challenge” study in which healthy young volunteers were deliberately infected with the virus. The study, carried out by a team led by researchers at Imperial College London, is the first to watch what happens from the moment someone is infected with SARS-CoV-2.

The findings: The 36 volunteers, all aged 18 to 30, were exposed to a low dose of the original SARS-CoV-2 virus in the nose, the equivalent of the amount found in just a single drop of nasal fluid. Half the participants developed covid symptoms; they became infectious within just two days, with levels of infectious virus peaking at five days. It has previously been estimated that the time from exposure to first symptoms was about five days. Participants in the study remained infectious for an average of nine days and still had detectable levels of virus in their nose 12 days after initial exposure.

Almost all the volunteers lost their sense of smell and experienced cold-like symptoms such as a runny nose and sore throat. None reported serious symptoms.  Some of the patients were also given the antiviral drug remdesivir before they were infected, but the trial didn’t pick up any noticeable difference in the severity of the symptoms.

What it all means: The findings come with the caveat that they’ve been derived from a small pool of volunteers, and they were published in a preprint paper that has not yet been peer-reviewed. However, they provide useful insights nonetheless. The fact that people become infectious so quickly and stay infectious for so long suggests that recommended isolation periods should be kept at around 10 days. Although the virus was detected in the throat first, it was eventually present at much greater levels in the nose, highlighting the need to wear face masks properly so they cover the nose.

Get tested: The research also supports the regular, widespread use of lateral flow testing. Modeling using the study data found that regular rapid tests can diagnose infection before 70% to 80% of infectious virus had been generated, meaning that if people get tested regularly and isolate when positive, it could significantly cut community transmission. The fact that none of the participants fell severely ill also suggests this trial method could be used to test future variants or drugs. 

Michael Jacobs, a consultant in infectious diseases at the Royal Free London hospital, where the trial was carried out, said in a statement: “The trial has already provided some fascinating new insights into SARS-CoV-2 infection, but perhaps its greatest contribution is to open up a new way to study the infection and the immune responses to it in great detail and help test new vaccines and treatments.”

Deep Dive

Biotechnology

This nanoparticle could be the key to a universal covid vaccine

Ending the covid pandemic might well require a vaccine that protects against any new strains. Researchers may have found a strategy that will work.

How do strong muscles keep your brain healthy?

There’s a robust molecular language being spoken between your muscles and your brain.

The quest to show that biological sex matters in the immune system

A handful of immunologists are pushing the field to take attributes such as sex chromosomes, sex hormones, and reproductive tissues into account.

This company is about to grow new organs in a person for the first time

A volunteer with severe liver disease will soon undergo a procedure that could lead them to grow a second liver.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.